BCEL - Atreca Inc Stock Price, Fair Value and News

$0.09

Market Closed

BCEL Stock Valuation Analysis

Valuation

Max Portfolio %

BCEL Price Action

BCEL RSI Chart

BCEL Stock Valuation Analysis

Valuation

Max Portfolio %

BCEL Valuation

BCEL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCEL Fundamentals

BCEL Earnings

BCEL Profitability

BCEL Investor Care

Revenue & Growth

About Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

CEO	Mr. John A. Orwin M.B.A.
WEBSITE	atreca.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	90